Year | Author | Multicenter | Therapeutic purpose | Antifungals | Sample size | Age | Underlying Disease | Dosing regimen | Duration |
---|---|---|---|---|---|---|---|---|---|
2001 | Ally | Y | D | VRC | 200 | 18–75 | Esophageal Candidiasis, AIDS | 200 mg, oral, bid | 14d |
FLU | 191 | 18–76 | Esophageal Candidiasis, AIDS | 200 mg, oral, qd | 15d | ||||
2002 | Lazarus | Y | P | VRC | 18 | 23–61 | HM & solid tumor | 200/300 mg, oral, q12h | 14d |
FLU | 6 | 23–62 | HM & solid tumor | 400 mg, oral, qd | 14d | ||||
2002 | Herbrecht | Y | D | VRC | 144 | 48.5 | HM, SOT, AIDS | 200Â mg, oral/i.v., bid | 77d |
AMBD | 133 | 50.5 | HM, SOT, AIDS | 1–1.5 mg/kg, i.v., qd | 10d | ||||
2002 | Walsh | Y | E | VRC | 415 | 46.3 | FN, HM or other cancers | 200Â mg, oral, q12h | 7d |
LAMB | 422 | 45 | FN, HM or other cancers | 3Â mg/kg, i.v. qd | 7d | ||||
2005 | Kullberg | Y | D | VRC | 248 | 53.6 | Candidaemia | 200Â mg, bid | 15d |
AMB/FLU | 122 | 53.3 | Candidaemia | AMB 0.7–1.0 mg/kg, oral/i.v., qd, | 15d | ||||
Flu, 400Â mg, oral/i.v. qd | |||||||||
2007 | Queiroz-Telles | Y | D | VRC | 35 | 48.3 | Paracoccidioidomycosis | 200Â mg, oral, bid | 169d |
ITRA | 18 | 48.7 | Paracoccidioidomycosis | 100Â mg, oral, bid | 200d | ||||
2010 | Wingard | Y | P | VRC | 305 | 43 | AHSCT | 200Â mg, oral, bid | 100d |
FLU | 295 | 43 | AHSCT | 400Â mg, oral, qd | 100d | ||||
2010 | Kohno. | Y | D | VRC | 54 | 69.9 | Tuberculosis sequelae | 4Â mg/kg, i.v., bid | 3w |
MCF | 53 | 72.1 | Tuberculosis sequelae | 150–300 mg, i.v., qd | 3w | ||||
2010 | Oyake 1 | Y | E | VRC | 46 | NA | FN patients with AML | 4Â mg/kg, i.v., bid | 9d |
MCF | 49 | NA | FN patients with AML | 150Â mg, i.v., qd | 10d | ||||
2011 | Bansal | N | D | VRC | 15 | 36.3 | CISA | 200Â mg (adults), 100Â mg (children), oral, q12h; | 12w |
AMB | 18 | 36.3 | CISA | 1Â mg/kg, i.v., qd | 14w | ||||
2011 | Mattiuzzi | N | P | VRC | 71 | 36.3 | AML + MDS | 300 mg, i.v., bid | 20d |
ITRA | 52 | 60 | AML + MDS | 200 mg, i.v., qd | 21d | ||||
2012 | Shang | Y | D | VRC | 34 | 37.5 | Kidney transplant | 4Â mg/kg, i.v., q12h | 2.9Â m |
MCF | 31 | 39.2 | Kidney transplant | 100Â mg (<60Â kg), qd; | 3.8Â m | ||||
150Â mg (>60Â kg), i.v., qd | |||||||||
2013 | Gao | Y | P | VRC | 224 | 42.3 | AHSCT | 200/100Â mg, oral/i.v., bid | 96d |
ITRA | 241 | 42.3 | AHSCT | 200Â mg, oral/i.v., bid | 68d | ||||
2014 | Hayashi | Y | P | VRC | 33 | NA | AHSCT | 200Â mg, oral, bid | NA |
ITRA | 33 | NA | AHSCT | 2.5Â mg/kg, oral/i.v., bid | NA | ||||
2016 | Maertens | Y | D | VRC | 258 | 51.2 | HM | 4Â mg/kg/200Â mg, oral/i.v., bid | 47d |
ISA | 258 | 51.1 | HM | 200Â mg, oral/i.v., qd | 45d | ||||
2016 | Oyake 2 | Y | E | VRC | 50 | 53 | FN with hematopathy | 4Â mg/kg, i.v., bid | 9d |
MCF | 50 | 53 | FN with hematopathy | 150Â mg, i.v., qd | 12d |